4547:TYO
Kissei Pharmaceutical Co Ltd
3Â 735,00Â JPÂ¥
arrow_downward
-1,32%(-50,00) 1K
29-sen, 15:30:00 (GMT+9) · JPY
search
Barcha belgilar
1K
5K
1O
6O
YBB
1Y
5Y
MAKS
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_auto4547 tikeri uchun statistika yaratilmoqda...
Ochish
3Â 800Â JPÂ¥
Yuqori
3Â 815Â JPÂ¥
Past
3Â 735Â JPÂ¥
Bozor kapitali
173,83Â mlrd
Oʻrtacha hajm
60,66Â ming
Hajmi
114,50Â ming
Dividend
3,21%
Choraklik dividendlar
30Â JPÂ¥
Eks-dividend sanasi
29-sen, 2026
P/E koeffitsiyenti
11,07
52 haftalik eng yuqori
5Â 040Â JPÂ¥
52 haftalik eng past
3Â 500Â JPÂ¥
Aksiya boʻyicha daromad
337Â JPÂ¥
Muomaladagi aksiyalar
46,72Â mln
Xodimlar soni
2Â ming
Ochish
3Â 800Â JPÂ¥
Yuqori
3Â 815Â JPÂ¥
Past
3Â 735Â JPÂ¥
Bozor kapitali
173,83Â mlrd
Oʻrtacha hajm
60,66Â ming
Hajmi
114,50Â ming
Dividend
3,21%
Choraklik dividendlar
30Â JPÂ¥
Eks-dividend sanasi
29-sen, 2026
P/E koeffitsiyenti
11,07
52 haftalik eng yuqori
5Â 040Â JPÂ¥
52 haftalik eng past
3Â 500Â JPÂ¥
Aksiya boʻyicha daromad
337Â JPÂ¥
Muomaladagi aksiyalar
46,72Â mln
Xodimlar soni
2Â ming
Profil
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
Kissei Pharmaceutical Co Ltd haqida
CEOMutsuo Kanzawa
Xodimlar soni1,79Â ming
Asos solingan9-avg, 1946
Bosh ofislarMatsumoto, Nagano, Yaponiya
Sektor-
Veb-saytkissei.co.jp